AstraZeneca has presented new data from the SERENA-6 trial of camizestrant in advanced breast cancer that it hopes will persuade the FDA to approve the oral selective oestrogen receptor degrader (SERD). The company has unveiled ctDNA clearance data that links early molecular response to extended progression‑free survival, aiming to convince the FDA that switching to camizestrant upon detection of an ESR1 mutation in blood is a meaningful advance in HR+ breast cancer care. The data are being highlighted at ASCO26, ahead of an extended FDA review decision on the drug
Sources:
FDA delays ruling on AstraZeneca drug after negative adcomm vote
AstraZeneca's record seventh year of plenary data at ASCO furthers ...
Europe Approves AstraZeneca's Camizestrant After FDA Advisory ...
AstraZeneca drug could help keep a common breast cancer at bay
April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee
FDA flags concerns for AZ's camizestrant, Truqap ahead of adcomm
AstraZeneca's breast cancer pill hit with review delay after negative ...
AstraZeneca's Camizestrant Faces FDA ODAC Review In ESR1 ...
AstraZeneca's record seventh year of plenary data at ASCO ...
FDA to end 9-month advisory committee drought with April ...
After negative adcomm, AZ builds case for oral SERD